Welcome to our dedicated page for Inspire Medical SEC filings (Ticker: INSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inspire Medical Systems filings document formal disclosures for a medical technology company commercializing neurostimulation therapy for obstructive sleep apnea. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information, Regulation FD presentation materials, tax-related events and officer or compensation matters.
Proxy and annual-meeting filings describe director elections, stockholder voting, executive compensation, equity incentive plan authorization and governance provisions, including charter and bylaw matters. These records also disclose common stock award reserves and the governance framework for a company selling Inspire therapy through hospitals and ambulatory surgery centers.
Inspire Medical Systems, Inc. reported that it has issued a press release with certain preliminary, unaudited financial results for the quarter and full year ended December 31, 2025, which are still subject to closing procedures and internal control review.
The company’s board appointed Matthew J. Osberg as Chief Financial Officer, to become effective the day after Inspire files its Annual Report on Form 10-K for 2025. He will also serve as principal financial officer and principal accounting officer. His employment agreement provides a $650,000 annual base salary, a target annual cash bonus equal to 70% of base salary, a $600,000 cash sign-on bonus, and long-term equity incentives in the form of performance stock units and restricted stock units valued at $1,500,000 each on the grant date.
As part of the planned finance leadership transition, Richard J. Buchholz has been appointed interim Chief Financial Officer and designated as interim principal financial officer and interim principal accounting officer through the filing of the 2025 Form 10-K. Inspire also plans investor and analyst meetings in January 2026, supported by an investor presentation made available on its website.
Inspire Medical Systems insider trading report: Chief Product and Innovation Officer John Rondoni reported selling 109 shares of Inspire Medical Systems common stock on January 9, 2026 at a price of $100 per share. After this sale, he beneficially owns 13,797 shares of the company’s stock.
The filing notes that all sale transactions reported were made under a Rule 10b5-1 trading plan dated May 28, 2025, which is a pre-arranged plan intended to allow executives to sell shares over time. The reported holdings include 140 shares acquired through the company’s 2018 Employee Stock Purchase Plan since a prior Form 4 dated May 21, 2025.
An INSP shareholder filed a Rule 144 notice to sell 109 shares of common stock. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC at an aggregate market value of $10,355.00, with the shares listed on the NYSE. The shares were acquired on 06/28/2024 through an employee stock purchase plan from the issuer for cash, and the planned sale date is approximately 01/09/2026. By signing the notice, the seller represents they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Inspire Medical Systems, Inc. director insider sale reported
Director Shawn T. McCormick reported selling 1,200 shares of Inspire Medical Systems, Inc. common stock on 12/02/2025 at a price of $139 per share. After this transaction, he beneficially owns 24,846 shares directly and 3,000 shares indirectly through a trust. The filing notes that all sale transactions were made under a Rule 10b5-1 trading plan dated August 29, 2025, which is a pre-arranged plan for trading company stock.
Inspire Medical Systems had an affiliate file a Form 144 notice to potentially sell 1,200 shares of its common stock through Morgan Stanley Smith Barney LLC on or about 12/02/2025. The shares have an aggregate market value of $151,608.00 based on the information provided. Common shares outstanding were 29,056,434 at the time referenced. The seller acquired these 1,200 shares on 03/17/2023 by exercising stock options and paying in cash on that date.
Over the past three months, the same account conducted 10b5-1 sales of 2,000 common shares on 11/28/2025, generating gross proceeds of $254,960.00. The notice includes a representation that the seller does not know of undisclosed material adverse information about the issuer’s current or prospective operations.
Inspire Medical Systems director reports planned stock sale
A director of Inspire Medical Systems reported selling 2,000 shares of common stock on 11/28/2025 at a price of $127.48 per share. After this sale, the director beneficially owns 26,046 shares directly and 3,000 shares indirectly through a trust. The filing notes that all sale transactions were made under a Rule 10b5-1 trading plan dated August 29, 2025, which is a pre-arranged program for trading company stock.
An affiliate of the issuer filed a Form 144 notice to sell 2,000 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate aggregate market value of $254,660. The filing lists total shares of this class outstanding as 29,056,434.
The shares to be sold were acquired on 03/17/2023 by exercising stock options granted by the issuer, with the purchase price paid in cash on the same date. This notice reflects a planned sale by or for the account of a person related to the issuer under Rule 144, and includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Inspire Medical Systems, Inc. (INSP) director Myriam J. Curet, M.D. reported several small transactions in the company’s common stock on a Form 4. The filing shows open‑market purchases and sales between $77.2754 and $163.8388 per share, leaving her with 3,365 shares of common stock held directly after the last reported transaction on 08/08/2025.
The filing explains that some trades occurred inadvertently through a pooled investment vehicle that did not filter out Inspire’s securities. It also notes that a May 8, 2025 sale of 1 share at $153.2237 was matchable under Section 16(b) with a prior April 7, 2025 purchase of 1 share at $148.262. Dr. Curet paid the company $4.97, representing the full short‑swing profit from that transaction.
Inspire Medical Systems, Inc. expects to release a significant portion of the valuation allowance on its U.S. deferred tax assets in the fourth quarter of fiscal 2025. The company estimates this action will create an income tax benefit of $90 million to $100 million for the year. This tax benefit is expected to increase diluted earnings per share by approximately $3.00 to $3.30 for the same period. These figures are based on current assumptions and are described as forward-looking, with actual results potentially differing due to various risks and uncertainties discussed in the company’s other regulatory filings.
Inspire Medical Systems (INSP): Schedule 13G/A update — Dragoneer Investment Group, LLC and Marc Stad filed Amendment No. 1 reporting beneficial ownership of the company’s common stock at 0 shares, representing 0% of the class.
The filing notes ownership of 5 percent or less and lists no voting or dispositive power. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The date of event is 09/30/2025.